Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.05 USD

103.05
5,144,767

-1.78 (-1.70%)

Updated Aug 6, 2025 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

AL vs. WAB: Which Stock Is the Better Value Option?

by Zacks Equity Research

AL vs. WAB: Which Stock Is the Better Value Option?

Zacks Equity Research

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

NEXA or WPM: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NEXA vs. WPM: Which Stock Is the Better Value Option?

Zacks Equity Research

ODP or ULTA: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ODP vs. ULTA: Which Stock Is the Better Value Option?

Sridatri Sarkar headshot

BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?

by Sridatri Sarkar

Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.

Sridatri Sarkar headshot

Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock

by Sridatri Sarkar

Boston Scientific rides strong cardiovascular momentum, with booming EP and WATCHMAN sales despite macro headwinds. What is the investment outlook?

Zacks Equity Research

Boston Scientific (BSX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Boston Scientific (BSX) closed at $102.43, indicating a -0.65% shift from the previous trading day.

Urmimala Biswas headshot

Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks

by Urmimala Biswas

BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.

Zacks Equity Research

Here's Why Boston Scientific (BSX) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Sridatri Sarkar headshot

Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?

by Sridatri Sarkar

BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.

Zacks Equity Research

Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $104.50, marking a -0.01% move from the previous day.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues

by Zacks Equity Research

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Zacks Equity Research

Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs

by Zacks Equity Research

Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.

Zacks Equity Research

Should You Continue to Hold Medtronic Stock in Your Portfolio Now?

by Zacks Equity Research

Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.

Zacks Equity Research

GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use

by Zacks Equity Research

GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.

Zacks Equity Research

Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered

by Zacks Equity Research

ALC ends the first quarter of 2025 on a disappointing note.

Zacks Equity Research

Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?

by Zacks Equity Research

Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.